Bleeding and Thrombotic Complications in COVID-19-Associated ARDS Requiring ECMO
Related Experiment Video
Updated: Aug 21, 2025

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
Eduardo P Tavares1, José R Rebolo2, Rodrigo Pimentel2
1Faculty of Medicine of Porto, Porto, Portugal.
Insights
Patients with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) experienced more severe bleeding complications and longer treatment durations compared to other ARDS causes. Further research is needed to assess ECMO
Area of Science:
- Critical Care Medicine
- Pulmonology
- Infectious Diseases
Background:
- Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition.
- Extracorporeal Membrane Oxygenation (ECMO) is a life support treatment for severe ARDS.
- COVID-19 has been associated with a unique ARDS presentation.
Purpose of the Study:
- To compare bleeding and thrombotic complications in COVID-19-associated ARDS versus other causes of ARDS requiring ECMO.
- To analyze clinical outcomes and ECMO course in COVID-19 ARDS patients.
Main Methods:
- A single-center observational study included adult patients undergoing ECMO for COVID-19 ARDS (n=67) or other ARDS (n=60).
- Exclusion criteria included trauma patients.
- Data on complications, laboratory values, and clinical outcomes were collected and compared.
Main Results:
- COVID-19 ARDS patients had lower invasive mechanical ventilation duration before ECMO and less frequent ECMO retrieval.
- Despite similar thrombotic complications and predicted survival scores, COVID-19 ARDS showed higher rates of severe bleeding (airway bleeding, hemothorax), lower hemoglobin, and increased red blood cell transfusions.
- COVID-19 ARDS was associated with significantly longer ECMO duration (47 days vs 19 days) but no significant difference in in-hospital mortality.
Conclusions:
- COVID-19-associated ARDS requiring ECMO is characterized by a high incidence of severe bleeding complications and prolonged treatment duration.
- Further investigation is warranted to fully understand the risks and benefits of ECMO in severe COVID-19 ARDS.
- Clinical management strategies may need to be adapted for COVID-19 ARDS patients on ECMO, particularly regarding bleeding risk.
Background:
We analyzed bleeding and thrombotic complications in COVID-19-associated ARDS requiring extracorporeal membrane oxygenation (ECMO).
Methods:
This was a single-center observational study of adult subjects undergoing ECMO for COVID-19 (n = 67) or all other cause of ARDS (n = 60), excluding trauma patients.
Results:
In the COVID-19 group, duration of invasive mechanical ventilation prior to ECMO was lower (2 [0-4] d vs 3 [1-6] d) and ECMO retrieval less frequent (71% vs 87%). No significant differences were found in Simplified Acute Physiology Score II, Acute Physiology and Chronic Health Evaluation II (APACHE II), or in the in-hospital survival predicted by the Respiratory ECMO Survival Prediction score. During the first 7 d of ECMO support, the COVID-19 group presented higher platelets and fibrinogen, lower activated partial thromboplastin time, but no differences in D-dimer. Thrombotic complications were similar between groups. Higher rates of severe bleeding, namely airway bleeding (37.3% vs 15.0%) and hemothorax (13.4% vs 3.3%), were found in COVID-19, with lower hemoglobin and higher red blood cell transfusions. COVID-19 ARDS was associated with longer ECMO duration (47 [17-80] d vs 19 [12-30] d) and absence of a statistically significant difference concerning in-hospital mortality.
Conclusions:
COVID-19-associated ARDS requiring ECMO presented high rates of severe bleeding complications and a protracted course. Further studies are needed to clarify the risks and benefits of ECMO in severe COVID-19-associated ARDS.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pneumonia III: Complications and Assessment
Venous Thrombosis III: Interprofessional Care

